化坚拔毒膜联合盐酸羟考酮缓释片治疗中重度癌性疼痛  

To observe the clinical efficacy of Huajian-Badu membrane in the treatment of moderate and severe cancer pain

作　　者：刘昭[1] 李小江[1] 张洪[1] 牟睿宇 郭姗琦[1] 贾英杰[1] Liu Zhao;Li Xiaojiang;Zhang Hong;Mou Ruiyu;Guo Shanqi;Jia Yingjie(Department of Oncology, the First Teaching Hospital of Tianjin University of Chinese Medicine in Oncology, Tianjin 300381, China)

机构地区：[1]天津中医药大学第一附属医院肿瘤科,300381

出　　处：《国际中医中药杂志》2019年第3期234-237,共4页International Journal of Traditional Chinese Medicine

基　　金：天津市科技计划项目(15ZXLCSY00020、2016004、2017119).

摘　　要：目的观察化坚拔毒膜联合盐酸羟考酮缓释片治疗中重度癌性疼痛的疗效。方法将符合入选标准的80例恶性肿瘤伴中重度癌性疼痛患者采用随机数字表法分为2组,每组40例。对照组服用盐酸羟考酮缓释片,观察组在对照组基础上外敷化坚拔毒膜,2组均治疗14 d。观察2组患者治疗后疼痛缓解情况、爆发痛次数、吗啡用量及Karnofsky评分,记录毒副作用发生情况,评价临床疗效。结果观察组总有效率为95.0%(38/40)、对照组为80.0%(32/40),2组比较差异有统计学意义(χ^2=4.114,P=0.043)。观察组爆发痛次数治疗后7 d[(0.3±0.6)次比(0.8±0.7)次,t=-3.430]、14 d[(0.4±0.6)次比(0.9±0.8)次,t=-3.162]少于对照组(P<0.01);观察组吗啡用量治疗后7 d[(3.01±4.28)g比(5.62±6.37)g,t=-2.151]、14 d[(3.21±4.32)g比(7.84±7.76)g,t=-3.297]少于对照组(P<0.05或P<0.01);观察组Karnofsky评分治疗后7 d[(73.0±15.0)分比(66.0±12.0)分,t=2.305]、14 d[(77.0±13.0)分比(70.0±15.0)分,t=2.230]高于对照组(P<0.05)。治疗期间,观察组毒副作用发生率为25.0%(10/40)、对照组为20.0%(8/40),2组比较差异无统计学意义(χ^2=0.287,P=0.592)。结论化坚拔毒膜联合盐酸羟考酮缓释片可减少癌性疼痛患者爆发痛次数及吗啡用量,提高患者生活质量及临床疗效,且未发生明显的毒副作用。Objective To observe the clinical efficacy of Huajian-Badu membrane in the treatment of moderate and severe cancer pain. Methods The 80 malignant tumor patients with moderate to severe cancer pain from January 2016 to June 2017 in Tianjin University of Traditional Chinese Medicine First Teaching Hospital were recruited and randomly divided into the observation group and the control group, each of 40 cases. The control group were treated with Oxycodone Hydrochloride Prolonged-release Tablets, while the treatment group were treated with Huajian-Badu membrane on the basis of the treatment in control group. The pain relief, pain frequency, morphine consumption and quality of life (Karnofsky score), adverse reaction were evaluated between two groups before and after treatment. Results Compared with the control group, the total efficiency in the observation group was significantly higher (95.0% vs. 80.0%,χ^2=4.114, P=0.043). The frequency of breakthrough pain of two groups increased on the seventh and fourteenth treatment days(0.3 ± 0.6 times vs. 0.8 ± 0.7 times, t=-3.430 and 0.4 ± 0.6 times vs. 0.9 ± 0.8 times, t=-3.162), but the number of outbreaks of pain in the observation group significantly less than the control group (P<0.05 or P<0.01). The morphine injection dosage increased on the seventh and fourteenth treatment days (3.01 ± 4.28 g vs. 5.62 ± 6.37 g, t=-2.151 and 3.21 ± 4.32 g vs. 7.84 ± 7.76 g, t=-3.297), but the amount of the observtation group was significantly lower than that of control group (P<0.05 or P<0.01). The KPS score in the observation group increased significantly, and significantly higher than the control group on the seventh and fourteenth treatment days (73.0 ± 15.0 vs. 66.0 ± 12.0, t=2.305 and 77.0 ± 13.0 vs. 70.0 ± 15.0, t=2.230, P<0.05). The adverse reaction rate of the control group was 25%, while the the observation group was 20%. The difference between two groups was significant (χ^2=0.287, P=0.592). Conclusions The Huajian-Badu membrane combined Oxycodone Hydrochloride Pr

关 键 词：癌症疼痛 化坚拔毒膜 盐酸羟考酮缓释片 吗啡 止痛药(中药) 药物相关副作用及不良反应 

分 类 号：R730.5[医药卫生—肿瘤]